Your trusted source for investing success

Tag: biopharmaceutical

10 Top 3D Printing Companies

10 Top 3D Printing Companies

It’s expected that the 3D Printing market will be worth over $30 billion by 2022. Here, the Investing News Network looks at 10 of the big players in the industry.

DelMar Pharmaceuticals Presents Poster at AACR’s Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer

DelMar Pharmaceuticals Presents Poster at AACR’s Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the presentation of a poster at the American Association for Cancer Research (AACR) Special Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment, being held October 1-4, 2017 in Pittsburgh, PA.  The poster entitled “Distinct mechanism of

DelMar Pharmaceuticals Announces Fiscal Year 2017 Financial Results

DelMar Pharmaceuticals Announces Fiscal Year 2017 Financial Results

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced its financial results for the year ended June 30, 2017.   DelMar executive management will host a business update conference call and live webcast for investors, analysts and other interested parties on Wednesday, October 4, 2017 at 4:30

DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer

DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer

 DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that it will be presenting an abstract at the American Association for Cancer Research (AACR) Special Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment, being held on October 1-4, 2017 in Pittsburgh, PA at the Wyndham Grand.

DelMar

DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market

DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that it has closed on its previously announced registered direct offering, priced at-the-market.  Pursuant to securities purchase agreements entered into with certain institutional investors, DelMar sold an aggregate of 8,000,000 shares of common stock

DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083

DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued to DelMar, United States Patent No. 9,759,698 covering improved analytical methods for analyzing and determining impurities in dianhydrogalactitol (VAL-083).

DelMar’s new patent strengthens the Company’s control over

5 Top Biotech Stocks on the TSX Year-to-date

5 Top Biotech Stocks on the TSX Year-to-date

The biotech sector has steadily enjoyed an increase this year, in part thanks to significant advancements and in spite of the uncertainty from the White House as the proposal of a new healthcare bill holds the grip of most life science markets.

DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer

DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has allowed an additional Investigational New Drug Application (“IND”) to study its lead drug candidate VAL-083 as a potential treatment for ovarian cancer.

 “The opening of this

CanniMed Therapeutics Inc. Reports Financial Results for Q3 2017

CanniMed Therapeutics Inc. Reports Financial Results for Q3 2017

CanniMed Therapeutics Inc. (TSX:CMED) (“CanniMed” or the “Company”) today released its financial results for the three and nine months ended July 31, 2017.

Highlights

Sales of $4.8 million in the quarter were 80 per cent higher than in the comparable period of the prior year and were 29 per cent higher than the second quarter of 2017.

DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme

DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the initiation of a Phase 2 clinical trial for its lead agent VAL-083 in newly diagnosed MGMT-unmethylated glioblastoma multiforme (GBM). The biomarker-driven clinical trial will explore safety and efficacy of chemoradiation with VAL-083 as

Canadian Marijuana Stocks

Canadian Marijuana Stocks

The Canadian marijuana sector is one of the hottest growing sectors. Here’s a look at Canadian cannabis companies for investors to consider.

DelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 10-12, 2017

DelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 10-12, 2017

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that Jeffrey Bacha, president & CEO of the Company, will be presenting at the 19th Annual Rodman & Renshaw Global Investment Conference being held September 10-12, 2017, at the Lotte New York Palace Hotel in New York

Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
4 Top Pharma Stocks on the NASDAQ Year-to-date

URL: https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/top-pharma-stocks-nasdaq/